(AFX UK Focus) 2010-06-03 13:15 PREVIEW-Investors seek clarity on ArQule trial plan

(AFX UK Focus) 2010-06-03 13:15 PREVIEW-Investors seek clarity on ArQule trial plan
By Deena Beasley

Read more on Interactive Investor

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

Read more on News-Medical-Net

EnVivo Initiates Phase IIb Alzheimer’s Disease Trial For EVP-6124

EnVivo Initiates Phase IIb Alzheimer’s Disease Trial For EVP-6124
EnVivo Pharmaceuticals announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing …

Read more on Medical News Today

Icos: Biotechnology, Eli Lilly and Company, Amgen, Inflammation, Clinical trial, Antibody, Tadalafil, Erectile dysfunction, GlaxoSmithKline

Product Description
High Quality Content by WIKIPEDIA articles! Icos Corporation (trademark ICOS) was the largest biotechnology company in the U.S. state of Washington before it was sold to Eli Lilly and Company in 2007. Co-founded in 1989 by George B. Rathmann, a pioneer in the industry and Chief Executive Officer (CEO) and co-founder of Amgen, Icos focused on the development of drugs to treat inflammatory disorders. During its 17-year history, the company conducted clinical trials of 12 drugs, three of which reached the last phase of clinical trials. Icos also manufactured antibodies for other biotechnology companies. Icos is famous for tadalafil (Cialis), a drug used to treat erectile dysfunction. This drug was discovered by GlaxoSmithKline, developed by Icos, and manufactured and marketed in partnership with Eli Lilly. Boosted by an unique advertising campaign led by the Grey Worldwide Agency, sales from Cialis allowed Icos to become profitable in 2006. Cialis was the only drug developed by the company to be approved

Icos: Biotechnology, Eli Lilly and Company, Amgen, Inflammation, Clinical trial, Antibody, Tadalafil, Erectile dysfunction, GlaxoSmithKline

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …

D-Pharm Receives Agreement Letter On Special Protocol Assessment For DP-b99 Study – A Pivotal Phase III Trial In Acute …
D-Pharm Ltd (DPRM: TASE) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for a pivotal phase 3 trial (MACSI) of its neuroprotective agent DP-b99 in acute ischemic stroke patients. The SPA agreement letter indicates that “the design and planned analysis of the study adequately address the objectives …

Read more on Medical News Today

Next Page »